Literature DB >> 15204933

Suppression of human immunodeficiency virus replication in human brain tissue by nucleoside reverse transcriptase inhibitors.

Apsara Kandanearatchi1, Annapurna Vyakarnam, Sabine Landau, Ian Paul Everall.   

Abstract

Human immunodeficiency virus (HIV) infection of the brain is associated pathologically with neuronal damage and loss. Clinically cognitive impairments can develop, which in some can be improved by highly active antiretroviral therapy (HAART), whereas in others, the infection persists despite treatment. The efficacy of antiretrovirals to treat cognitive impairments may be related to their ability to suppress viral replication in the brain and also to prevent neurodegeneration. To investigate this question, the authors assessed the ability of stavudine (300 nM), zidovudine (2 nM), and abacavir (300 nM) to suppress viral replication in human brain tissue aggregates infected with HIV-1 SF162. Aggregates were cultured for 4 weeks and exposed to nucleoside reverse transcriptase inhibitors (NRTIs) either 24 h prior, simultaneously, or 24 h post infection. Viral replication was assessed by p24 enzyme-linked immunosorbent assay (ELISA) in culture medium. The authors observed a statistically significant reduction in the rate of viral replication for stavudine added 24 h prior to infection univariate analysis of variance ([UANOVA], t = 2.55, df = 17, P =.021). Decreased viral replication observed with zidovudine and abacavir was not statistically significant.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15204933     DOI: 10.1080/13550280490428379

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  14 in total

1.  Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center.

Authors:  I P Everall; R K Heaton; T D Marcotte; R J Ellis; J A McCutchan; J H Atkinson; I Grant; M Mallory; E Masliah
Journal:  Brain Pathol       Date:  1999-04       Impact factor: 6.508

2.  Neuronal loss in the frontal cortex in HIV infection.

Authors:  I P Everall; P J Luthert; P L Lantos
Journal:  Lancet       Date:  1991-05-11       Impact factor: 79.321

3.  Evaluation of antiretroviral drug efficacy for HIV-1 encephalitis in SCID mice.

Authors:  J Limoges; Y Persidsky; L Poluektova; J Rasmussen; W Ratanasuwan; M Zelivyanskaya; D R McClernon; E R Lanier; H E Gendelman
Journal:  Neurology       Date:  2000-01-25       Impact factor: 9.910

4.  Microdialysis studies of the distribution of stavudine into the central nervous system in the freely-moving rat.

Authors:  Z Yang; R C Brundage; R H Barbhaiya; R J Sawchuk
Journal:  Pharm Res       Date:  1997-07       Impact factor: 4.200

5.  Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group.

Authors:  R J Ellis; K Hsia; S A Spector; J A Nelson; R K Heaton; M R Wallace; I Abramson; J H Atkinson; I Grant; J A McCutchan
Journal:  Ann Neurol       Date:  1997-11       Impact factor: 10.422

6.  Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia.

Authors:  L Chang; T Ernst; M Leonido-Yee; M Witt; O Speck; I Walot; E N Miller
Journal:  Neurology       Date:  1999-09-11       Impact factor: 9.910

7.  A Na(+)-dependent nucleoside transporter in microglia.

Authors:  M Hong; L Schlichter; R Bendayan
Journal:  J Pharmacol Exp Ther       Date:  2000-01       Impact factor: 4.030

8.  Granulocyte-macrophage colony-stimulating factor enhances viral load in human brain tissue: amelioration with stavudine.

Authors:  Apsara Kandanearatchi; Mark Zuckerman; Melvyn Smith; Annapurna Vyakarnam; Ian P Everall
Journal:  AIDS       Date:  2002-02-15       Impact factor: 4.177

9.  HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement.

Authors:  J E Bell; R P Brettle; A Chiswick; P Simmonds
Journal:  Brain       Date:  1998-11       Impact factor: 13.501

10.  The transport of the anti-HIV drug, 2',3'-didehydro-3'-deoxythymidine (D4T), across the blood-brain and blood-cerebrospinal fluid barriers.

Authors:  S A Thomas; M B Segal
Journal:  Br J Pharmacol       Date:  1998-09       Impact factor: 8.739

View more
  2 in total

Review 1.  Neuropsychiatric complications of antiretroviral therapy.

Authors:  Michelle S Cespedes; Judith A Aberg
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial.

Authors:  Bruce J Brew; Mark Halman; Jose Catalan; Ned Sacktor; Richard W Price; Steve Brown; Hamp Atkinson; David B Clifford; David Simpson; Gabriel Torres; Colin Hall; Christopher Power; Karen Marder; Justin C Mc Arthur; William Symonds; Carmen Romero
Journal:  PLoS Clin Trials       Date:  2007-03-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.